Abstract
Dabrafenib is the second agent in the therapeutic class of selective BRAF inhibitors, and has proven efficacy in a phase III trial (BREAK-3) with impressive improvements in progression-free survival and response rates. Differences in the safety profile exist compared with vemurafenib, but the future lies in combinatorial strategies and improved patient selection.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 496-497 |
| Number of pages | 2 |
| Journal | Nature Reviews Clinical Oncology |
| Volume | 9 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2012 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
Fingerprint
Dive into the research topics of 'Targeted therapies: BREAKing a path for progress - Dabrafenib confirms class effect'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS